Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Dorn

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patientsJulia Dorn, Manfred Schmitt, Ronald Kates, et al.
Life (Basel, Switzerland)|October 27, 2022
A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA ExpressionYueyang Liu, Weiwei Gong, Sarah Preis, et al.
Expert Opinion on Therapeutic Targets|August 18, 2018
Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancerDaniela Loessner, Peter Goettig, Sarah Preis, et al.
Journal of Ovarian Research|October 22, 2020
Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancerWeiwei Gong, Yueyang Liu, Eleftherios P Diamandis, et al.
Plos One|February 28, 2019
Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patientsWeiwei Gong, Yueyang Liu, Christof Seidl, et al.
Plos One|November 3, 2017
Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancerXiaocong Geng, Yueyang Liu, Sandra Diersch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancerCarla A Borgoño, Tadaaki Kishi, Andreas Scorilas, et al.
Biological Chemistry|August 19, 2011
mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancerMatthias Kotzsch, Julia Dorn, Kristina Doetzer, et al.
Biological Chemistry|August 10, 2006
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinomaJulia Dorn, Nadia Harbeck, Ronald Kates, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 9, 2004
Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosisEleftherios P Diamandis, Carla A Borgoño, Andreas Scorilas, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patientsJulia Dorn, Manfred Schmitt, Ronald Kates, et al.
Life (Basel, Switzerland)|October 27, 2022
A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA ExpressionYueyang Liu, Weiwei Gong, Sarah Preis, et al.
Expert Opinion on Therapeutic Targets|August 18, 2018
Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancerDaniela Loessner, Peter Goettig, Sarah Preis, et al.
Journal of Ovarian Research|October 22, 2020
Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancerWeiwei Gong, Yueyang Liu, Eleftherios P Diamandis, et al.
Plos One|February 28, 2019
Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patientsWeiwei Gong, Yueyang Liu, Christof Seidl, et al.
Plos One|November 3, 2017
Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancerXiaocong Geng, Yueyang Liu, Sandra Diersch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancerCarla A Borgoño, Tadaaki Kishi, Andreas Scorilas, et al.
Biological Chemistry|August 19, 2011
mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancerMatthias Kotzsch, Julia Dorn, Kristina Doetzer, et al.
Biological Chemistry|August 10, 2006
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinomaJulia Dorn, Nadia Harbeck, Ronald Kates, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 9, 2004
Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosisEleftherios P Diamandis, Carla A Borgoño, Andreas Scorilas, et al.
Pageof 6